6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
about
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3In situ assembly of enzyme inhibitors using extended tetheringDiscovery of Novel Irreversible Inhibitors of Interleukin (IL)-2-inducible Tyrosine Kinase (Itk) by Targeting Cysteine 442 in the ATP PocketOptimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitorsCovalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition ReactionsDesign, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common featuresInduction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component.Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones and Evaluation of their Anticancer and Antimicrobial Activities.An NMR-Guided Screening Method for Selective Fragment Docking and Synthesis of a Warhead Inhibitor.Rapid synthesis and antiviral activity of (quinazolin-4-ylamino)methyl-phosphonates through microwave irradiation.A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazolineImaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.Imaging EGFR and HER2 by PET and SPECT: a review.Chemical Protein Modification through Cysteine.Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70.Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer.Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting EGFR.6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors.Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase.Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives.3-(2-Amino-eth-yl)-2-[4-(trifluoro-meth-oxy)anilino]quinazolin-4(3H)-one.2-[2-(2-Anilino-4-oxo-3,4-dihydro-quinazolin-3-yl)phen-oxy]-3-phenyl-quinazolin-4(3H)-one methanol hemisolvate.2-Anilino-3-(2-hy-droxy-phen-yl)quinazolin-4(3H)-one methanol monosolvate.Oxidative dehydrogenation of C-C and C-N bonds: A convenient approach to access diverse (dihydro)heteroaromatic compounds.3-(2-Hydroxy-ethyl)-2-(p-tolyl-amino)-quinazolin-4(3H)-one.A crosslinker based on a tethered electrophile for mapping kinase-substrate networks.3,3'-Bis(4-chloro-phen-yl)-2,2'-(m-phenyl-enedi-oxy)diquinazolin-4(3H)-one.Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.3-(2-Amino-ethyl)-2-(4-chloro-anilino)-quinazolin-4(3H)-one methanol 0.75-solvate.The acid-catalysed synthesis of 7-azaindoles from 3-alkynyl-2-aminopyridines and their antimicrobial activity.Synthesis and evaluation of novel 4-substituted styryl quinazolines as potential antimicrobial agents.An approach towards azafuranomycin analogs by gold-catalyzed cycloisomerization of allenes: synthesis of (αS,2R)-(2,5-dihydro-1H-pyrrol-2-yl)glycine.Synthesis of oxazocenones via gold(I)-catalyzed 8-endo-dig hydroalkoxylation of alkynamides.Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
P2860
Q24633878-BA1B01C3-A040-4886-8941-89BB27B92918Q27640418-EF710770-414D-4DDF-9A1F-131D4D62E8E8Q27679513-9772F8C8-DCAE-48E7-8BE5-1F1BB3C7B457Q28535038-39F1234E-50A5-4679-BDE7-BAAEDF9576C5Q29248430-2614D279-0BA3-4F47-A456-BC71C793C2A8Q33635960-56913A2B-E174-48E9-8227-20E3AE35F3B2Q34067085-F96152BC-9981-4C20-8CA9-AEF7D6896CABQ34976925-4F24A1E5-3A30-4F65-BE1E-53CB91CE43E7Q35032547-5EEF3DB0-9C08-4CFF-831E-ED64F4CE0667Q35801308-BDB356BA-9B75-4A58-AFED-69DA67CAE59DQ36083038-2154AD10-BDB9-4B35-AC17-5FBA1FC6AE07Q36096891-F626D212-6183-4011-B9C9-E6C8FA70368CQ36902441-6FB70BD3-302C-49A4-99FE-2259A3AEA60CQ37320501-BC00A583-9328-4955-A2FA-BA402B14CB1CQ37475183-9FEFF577-9388-4DEB-B85E-3078BED6EFCDQ38137829-5924CFEC-3F91-404F-A4F0-FB8598970F5FQ38704033-BEA903B3-B3DF-467E-9AFB-6C1FDAFA8B4AQ38705732-22ADBA21-C45A-471F-AE50-77A381938083Q38737302-D293CCE5-61B4-4F0B-923C-215AF00F62E3Q38766833-BB6F540D-4B52-48B2-89AC-9F4A818E252FQ38992642-C8BAECF5-05EA-4789-B461-899A0649E6D6Q39126918-76DD4DC0-4E1E-4278-BAE3-9E6F8EF0F3ADQ39156749-46D1660F-A4FB-4579-9AE0-4BDD383E0CAEQ39238873-74105A5E-319D-44DB-B3CC-9D5B4257F770Q39687568-64E85E2B-F63A-4227-AA13-1ABE8108F4C1Q40241230-CA8C74BC-E6FF-4E34-9BDF-A84FC632C0A9Q41341200-AD8E49B3-C69C-472D-AE24-D763F1751E6DQ41370296-03261347-E0FE-4E61-B43C-0E7C65F8C97EQ41398951-9726EF8C-C15C-4E9D-892D-F44A974E3E8CQ41469033-04963162-572D-46C9-81ED-048D03B09AD4Q42008249-CF5577B5-301C-40E0-AAE1-CD93DA212E22Q42010790-1122C6E5-E561-4833-9E9B-FAFDB46F0000Q42107814-467CE9CF-9678-4EA4-9708-6E220C6D363AQ42173414-81A49CE1-B738-4EBE-A1AA-916A9A5FE72EQ42390708-E0489B6C-34B8-4823-B9F7-A0CB07F2CB65Q42708414-B301D6FE-56EC-46B3-8445-79CC6D4B770FQ42715656-716E304C-B16A-46A2-A445-A32105A93EB8Q42921660-CB42C775-D153-4B2F-A45E-5A89F72C0FF7Q43141167-1DD93361-0FC1-450B-A26C-DDBA0B62D957Q44124412-28F2C67A-F3B1-4695-BBED-61D6BE8BE00C
P2860
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@ast
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@en
type
label
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@ast
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@en
prefLabel
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@ast
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@en
P2093
P356
P1476
6-Substituted-4-(3-bromophenyl ...... h enhanced antitumor activity.
@en
P2093
Discafani C
Greenberger LM
Johnson BD
Nilakantan R
P304
P356
10.1021/JM0005555
P407
P577
2001-08-01T00:00:00Z